Congrats to colleagues & partners with numerous #arvo2022 presentations on #sup…
[ad_1]
Congrats to colleagues & partners with numerous #arvo2022 presentations on #suprachoroidal delivery, with the SCS Microinjector. In addition to FDA-approved #Xipere, 6 clinical trials globally are assessing 4 different investigational therapies, using the SCS Microinjector.#eye https://t.co/TFshyatTTH
[ad_2]
Source by Thomas Ciulla, MD, MBA